ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INSM Insmed Inc

69.86
-0.09 (-0.13%)
04 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Insmed Inc NASDAQ:INSM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.09 -0.13% 69.86 60.00 70.75 70.75 69.56 69.79 1,151,203 05:00:10

Insmed To Present at December 2024 Investor Conferences

02/12/2024 1:00pm

PR Newswire (US)


Insmed (NASDAQ:INSM)
Historical Stock Chart


From Nov 2024 to Jan 2025

Click Here for more Insmed Charts.

BRIDGEWATER, N.J., Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

  • Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 11:15 a.m. ET.
  • Nasdaq 51st Investor Conference held in association with Morgan Stanley in London on Wednesday, December 11, 2024, at 10:30 a.m. GT / 5:30 a.m. ET.

These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com

Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com

Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com

Media:

Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com

Insmed-Logo-Purple (PRNewsfoto/Insmed Incorporated)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-december-2024-investor-conferences-302313424.html

SOURCE Insmed Incorporated

Copyright 2024 PR Newswire

1 Year Insmed Chart

1 Year Insmed Chart

1 Month Insmed Chart

1 Month Insmed Chart

Your Recent History

Delayed Upgrade Clock